This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of imatinib for the treatment of chronic myelogenous leukemia; Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors; Tyrosine kinase inhibitors in the treatment of systemic mastocytosis and hypereosinophilic syndrome; The development and use of JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPN); Mechanisms of resistance to JAK2 inhibitors in MPN; Kinase inhibitor screening in myeloid malignancies; and more!
By:
Ann Mullally (Dana-Farber/Brigham and Women's Cancer Center) Imprint: Elsevier - Health Sciences Division Country of Publication: United States Volume: 31-4 Weight: 410g ISBN:9780323532358 ISBN 10: 0323532357 Series:The Clinics: Internal Medicine Publication Date:11 July 2017 Audience:
Professional and scholarly
,
Undergraduate
Format:Hardback Publisher's Status: Active